Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

DKTK Tübingen: Scientific excellence opens up new possibilities for cancer treatment

No. 01b | 08/01/2016 | by AM

This year’s Ernst Jung Award for Medicine will be awarded to DKTK scientist Professor Dr. Hans-Georg Rammensee. Rammensee’s research has been devoted to developing effective therapies individualized for each cancer patient, and the work of his lab represents important steps toward this goal. As an immunobiologist working at the DKTK partner site in Tübingen, Rammensee is considered a pioneer in the field of individualized cancer immunotherapy. For his outstanding work, Rammensee is now being awarded the Ernst Jung Award for Medicine, which is accompanied by a monetary prize of €300,000 – one of the highest in European medicine. He is a partner in the German Cancer Consortium (DKTK), through which the German Cancer Research Center (DKFZ) in Heidelberg is serving as a core center that is helping link university hospitals all over Germany that are specialized in research and treatment with a focus on oncological diseases.

Hans-Georg Rammensee
© Jung-Stiftung

“I am very pleased about this award,” says Rammensee. “It provides an incentive that will help us overcome the many obstacles that still lie ahead. Personalized cancer therapy has made enormous progress in recent years and it is now within reach.”

Cancer is diagnosed ever more frequently today. The latest cancer statistics for Germany suggest that every second person will be affected by cancer at some point during his or her lifetime. The chances for new cures and longer survival are better now than ever before. Yet there are more than 200 types of cancer that can affect various types of tissues, and the disease takes its own course in each affected individual. This creates the challenge of tailoring treatments to be effective against the cancer found in a single patient. This is where Rammensee’s work comes in. He studies the structure of molecular peptides on the cell surface that have an important function in diseases, because they provide information about the status of the cell's health that can be read by the immune system. If a patient's cancer cells produce unique peptides that scientists can identify, it may be possible to teach the immune system to recognize them as well. This would trigger an immune response that very specifically destroys only diseased cells. Since the cells of individual patients often produce different peptides, the success of therapies will likely depend on finding markers that are unique to each case of cancer.

Many of the findings from Rammensee's lab in Tübingen have already been translated into clinical practice, including treatments based on the development of advanced cancer vaccines. Rammensee has been involved in the German Cancer Consortium (DKTK) since 2011. His main wish for the future is to find ways to accelerate the processes by which the results of research can be translated into novel types of therapies. “We need new infrastructures to ensure that findings from research reach patients as quickly as possible," he says. "This is what makes translational research in medicine so important."

Rammensee has been studying the immune system and ways that it can be used to fight cancer for almost 30 years. He has worked in the USA, in Switzerland and at the German Cancer Research Center (DKFZ) in Heidelberg, Germany. In 1996, he received a professorship for immunology at Tübingen University, where he currently heads the Department of Immunology at the Interfaculty Institute for Cell Biology (IFIZ).

The award is named for the Hamburg ship owner, entrepreneur, philanthropist and benefactor Ernst Jung, who died on January 8, 1976. He was an ardent supporter of the medical sciences and established the Ernst Jung Foundation, based in Hamburg, partly as a means of promoting biomedical research. The Foundation commemorates the anniversary of his death by naming the recipients of several major awards. On the 40th anniversary this year, two additional scientists were honored. The 2016 Ernst Jung Gold Medal for Medicine goes to Professor Peter Libby, MD, an American scientist working at Harvard Medical School. Dr. med. Sebastian Kobold, a tumor researcher and Senior Academic Assistant at the University of Munich, was named as the winner of the Ernst Jung Career Advancement Award for Medical Research. The awards will be presented at a ceremony in Hamburg on May 21, 2016.

Pictures available at:

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS